Introduction: Renal cell carcinoma (RCC) is the most fatal of the common urologic cancers, with approximately 35% of patients dying within 5 years following diagnosis. Therefore, there is a need for non-invasive markers that are capable of detecting and determining the severity of small renal masses at an early stage in order to tailor treatment and follow-up. Proteomic studies have proved to be very useful in the study of tumors. Areas covered: In this review, we will detail the current knowledge obtained by the different proteomic approaches, focusing on MS-based strategies, used to investigate RCC biology in order to identify diagnostic, prognostic and predictive biomarkers on tissue, cultured cells and biological fluids. Expert commentary: Currently, no reliable biomarkers or targets for RCC have been translated into the clinical setting. Moreover, despite the efforts of proteomics and other-omics disciplines, only a small number of them have been observed as shared targets between the different analytical platforms and biological specimens. The difficulty to define a specific molecular pattern for RCC and its subtypes highlights a peculiar profile and a heterogeneity that must be taken into account in future studies.

Chinello, C., L'Imperio, V., Stella, M., Smith, A., Bovo, G., Grasso, A., et al. (2016). The proteomic landscape of renal tumors. EXPERT REVIEW OF PROTEOMICS, 13(12), 1103-1120 [10.1080/14789450.2016.1248415].

The proteomic landscape of renal tumors

CHINELLO, CLIZIA
Primo
;
L'Imperio, V;STELLA, MARTINA;SMITH, ANDREW JAMES;RAIMONDO, FRANCESCA;PITTO, MARINA;PAGNI, FABIO
Penultimo
;
MAGNI, FULVIO
Ultimo
2016

Abstract

Introduction: Renal cell carcinoma (RCC) is the most fatal of the common urologic cancers, with approximately 35% of patients dying within 5 years following diagnosis. Therefore, there is a need for non-invasive markers that are capable of detecting and determining the severity of small renal masses at an early stage in order to tailor treatment and follow-up. Proteomic studies have proved to be very useful in the study of tumors. Areas covered: In this review, we will detail the current knowledge obtained by the different proteomic approaches, focusing on MS-based strategies, used to investigate RCC biology in order to identify diagnostic, prognostic and predictive biomarkers on tissue, cultured cells and biological fluids. Expert commentary: Currently, no reliable biomarkers or targets for RCC have been translated into the clinical setting. Moreover, despite the efforts of proteomics and other-omics disciplines, only a small number of them have been observed as shared targets between the different analytical platforms and biological specimens. The difficulty to define a specific molecular pattern for RCC and its subtypes highlights a peculiar profile and a heterogeneity that must be taken into account in future studies.
Articolo in rivista - Articolo scientifico
Biological fluids; Biomarkers; Cancer; Kidney; Mass spectrometry imaging; Peptidome; Proteome; Proteomics; Renal cell carcinoma; Tissue;
Renal cell carcinoma; biological fluids; biomarkers; cancer; kidney; mass spectrometry imaging; peptidome; proteome; proteomics; tissue
English
1103
1120
18
Chinello, C., L'Imperio, V., Stella, M., Smith, A., Bovo, G., Grasso, A., et al. (2016). The proteomic landscape of renal tumors. EXPERT REVIEW OF PROTEOMICS, 13(12), 1103-1120 [10.1080/14789450.2016.1248415].
Chinello, C; L'Imperio, V; Stella, M; Smith, A; Bovo, G; Grasso, A; Grasso, M; Raimondo, F; Pitto, M; Pagni, F; Magni, F
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/133795
Citazioni
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
Social impact